AptarGroup, Inc. reported financial results for the third quarter of 2026, ending September 30. The company announced that reported sales increased 6% to $1.02 billion compared to the prior year period, while core sales increased 5%.
For the three months ended September 30, 2026, reported net income was $33 million, resulting in reported earnings per share of $0.51. This figure was impacted by the deconsolidation of its Russian subsidiary. Adjusted earnings per share were $1.52, compared to $1.62 in the prior year period at comparable exchange rates. Adjusted EBITDA margin was 21.3%, a decrease from 23.2% in the prior year quarter.
Segment performance varied by division. Pharma reported sales growth of 2%, with core sales growth of 1% before adjusting for emergency medicine destocking, which drove 8% growth in that specific area. Beauty reported reported sales growth of 9% and core sales growth of 8%. Closures reported reported sales growth of 11% and core sales growth of 11%, driven by beverage and food sales.
During the quarter, Aptar deconsolidated its Russian subsidiary following a governmental decree placing the entity under external administration. The company recorded a loss on deconsolidation of approximately $58 million before tax, which included approximately $30 million of cash held by the subsidiary. This resulted in a reported effective tax rate of 45.6% for the quarter.
Regarding capital allocation, Aptar returned $61 million to shareholders in the quarter, including $30 million spent on share repurchases. The company also announced an increase in its quarterly cash dividend to $0.50 per share, with a payment date of December 3, 2026.
Aptar provided guidance for the fourth quarter of 2026, expecting adjusted earnings per share to be in the range of $1.39 to $1.47. This guidance assumes an effective tax rate range of 17.5% to 19.5% and a 1.12 Euro to USD exchange rate.
